Galectin-3: clinical utility and prognostic value in patients with heart failure

Frank KramerClinical Sciences, Global Biomarker Strategy and Development, Bayer HealthCare, Wuppertal, GermanyAbstract: This review summarizes the key findings of 14 clinical trials in which Galectin-3 was assessed as a biomarker of heart failure. In addition, most relevant information available about Galectin-3 biology generated in in vitro and in vivo research is discussed in the context of heart failure.Keywords: biomarker, cardiovascular disease, therapy monitoring, prediction of outcome, patient stratification